Loading clinical trials...

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

NCT00626860•Beth Israel Deaconess Medical Center

View on ClinicalTrials.gov

Summary

This study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.

Detailed Description

To assess the toxicity associated with vaccination of melanoma patients with dendritic cell (DC)/tumor fusions. To determine if cellular and humoral immunity can be induced by serial vaccination with DC/tumor fusions cells. To determine if vaccination DC/tumor fusions results in a tumor response.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•patients with confirmed diagnoses of disseminated melanoma, with measurable and clearly progressive metastatic involevment
•Patients must be at least 18 years old
•Patients must have ECOG performance status 0-1 with greater than 9 week life expectancy
•Those patients with the following accessible tumor will be eligible: soft tissue, bone marrow or visceral lesions; Skin or superficial soft tissue, or lymph nodes amenable to resection under local anesthesia; Patients who require surgical procedures that are not considered significantly invasive but may require general anesthesia, such as thorascopic biopsy, laparascopic biopsy or mediastinal node biopsy may potentially be eligible; Malignant ascites or pleural effusion; Patients requiring major surgical intervention will be considered ineligible. Patients scheduled to undergo tumor resection for independent diagnostic or therapeutic indications may have tumor collected for the purposes of this study.
•Labs: WBC \>\_ 2.0 x 10x3/uL, Bilirubin \<\_2.0 mg/dL, Creatine \<\_ 2.0mg/dL
•Women of childbearing age must have a negative pregnancy test and adequate contraception method(s) must be documented
•All patients must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines

Exclusion Criteria

•Patients must not have received other immunotherapy treatment in the past four weeks prior to study entry
•Patients must not have received chemotherapy for three weeks prior to the first vaccination
•Patients must be without evidence of active CNS disease
•Patients must not have clinically significant autoimmune disease
•Patients must be HIV negative
•Patients must not have serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
•Patients requiring corticosteroids for either melanoma related or co-morbid illness

Locations (1)

BIDMC

Boston, Massachusetts, United States

Key Dates

Start Date

July 1, 2000

Primary Completion Date

January 1, 2002

Completion Date

September 10, 2008

Last Updated

January 23, 2026

Enrollment

ESTIMATED participants

Conditions

Metastatic Melanoma

Interventions

DC/tumor fusion vaccine

BIOLOGICAL

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGNA

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

NCT07112170

Metastatic MelanomaOligoProgressive Metastatic Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3